Road Rage Menace: A Cross-sectional Study to Assess Driver Anger Level in Public Motor Vehicle Drivers in a City in Central India

Introduction: Road rage and aggressive driving is a prevalent condition in today’s society due to motorists’ frustrations during heavy traffic volumes. Objective: This study was done to assess the level of anger amongst the drivers of public transport vehicles in Indore, using Driving Anger Scale (DAS by Deffenbacher et. al.) and various factors affecting it. Material and Methods: A cross-sectional study was conducted among 135 drivers of Public transport vehicle drivers (Star bus, City-van and star cab drivers) in Indore to assess their anger level using Driving Anger Scale. The participants were required to record the amount of anger they would experience in response to each item in the scale (1=not at all angry, 2=a little angry, 3=some anger, 4=much anger, 5=very much angry). Results: The mean DAS score in Indore was found to be 3.013 and in the three organizations namely Star bus drivers, City van drivers and Star cab drivers was 2.92, 3.08 and 3.04 respectively. The DAS score of drivers with respect to the 6 sub-scales were: hostile gestures (Star bus -3.42,City van -3.67,Star cab -3.38), slow driving (Star bus -2.73,City van driv-2.78,Star cab-3.17), traffic obstructions (Star bus-2.85,City van -3.25,Star cab-3.18), discourtesy (Star bus -3.23,City van-3.33,Star cab -3.25)and police presence (Star bus -2.15,City van -1.99,Star cab -2.78), illegal driving (Star bus -3.04,City van -3.14,Star cab -2.89). The DAS scores of the drivers did not vary significantly with age group, experience, and educational qualification. Conclusion: Though DAS scores did not vary between the three groups of drivers, however average level anger for various given circumstances commonly found in the Indian traffic scenario was on the higher side

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Optimization of regional hazardous waste management systems: an improved formulation

The planning and design of regional hazardous waste management system (RHWMS) involves selection of treatment and disposal facilities, allocation of hazardous wastes and waste residues from generator to the treatment and disposal sites and selection of the transportation routes. An improved formulation based upon multi-objective integer programming approach is presented to arrive at the optimal configuration of RHWMS components. This formulation addresses important practical issues like unique characteristics of the hazardous wastes reflecting on waste-waste and waste-technology compatibility. A utility function approach is presented to integrate both cost and risk related objectives. An illustrative case example is presented to demonstrate the usefulness of the improved formulation as a tool which can be used by environmental planning agencies in regional planning for hazardous waste management. (C) 1999 .

A strategic design approach for optimization of regional hazardous waste management systems

The planning and design of a regional hazardous waste management system involves selection of treatment and disposal technologies and sites, allocation of hazardous waste from generator to the sites and selection of thr transportation routes. To arrive at the optimum configuration of system components, the conventional approach uses the annual waste generation rate as the design criterion. This paper investigates limitations of this design criterion in detail and presents an improved strategic design approach. The strategic design approach is based on the adaptive use of cumulative hazardous waste generation and annual waste generation rates, Experience with the example problem solved shows its superiority over the conventional approach in terms of reduced cost as well as risk. Further, the solution identified by the proposed approach eliminates the possibility of exhaustion of disposal sites during the planning period, and therefore serves as a robust planning tool

Not Available

Not AvailableTO FIND OUT MOST EFFECTIVE METHOD OF SOIL AND WATER CONSERVATION IN TERRACED AREA IN RAVINE LANDS ( GUJARAT) FOR MAXIMUM PRODUCTION UNDER RAINFED CONDITIONS, FOUR TREATMENTS VIZ CONTOUR CULTIVATION ALONE AND CONTOUR CULTIVATION WITH CONTOUR FURROWS AFTER EVERY ONE, THREE AND SIX ROWS WERE EVALUATED IN AN UNREPLICATED TRIAL N 30 X 20 m PLOTS HAVING 2% SLOPE. THE TEST CROP WAS BIDI - TOBACCO - BAJRA IN TWO YEAR ROTATION. ON THE BASIS OF FOUR YEARS DATA, CONTOUR FURROWS AFTER EVERY THREE OR SIX ROWS RESULTED IN BETTER MOISTURE CONSERVATION LEAST RUNOFF AND SOIL LOSS AND HIGHER YIELDS.Not Availabl